Thus, the aim of this work was to evaluate the efficacy of PPRHs against the ERBB2 gene in HER-2-positive breast cancer cell lines, alone or in combination with the antibody trastuzumab, both in vitro and in vivo. This evidence concerns the gene ERBB2 and breast carcinoma.